# US 2022/0031720 A1 · Immunogenic compositions containing n-glycol ylneuraminic acid bearing nanoparticles

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031720 A1
- Document ID: US20220031720A1
- Status: Published application
- Kind: A1
- Application number: 17/296,504
- Filed: 2019-11-21
- Published: 2022-02-03
- Earliest claimed: 2018-11-22
- Assignees: Ramot at Tel-Aviv University Ltd.
- Applicants: Ramot At Tel-Aviv University Ltd.
- Inventors: Vered PADLER-KARAVANI; Eliran Moshe REUVEN; Shani LEVIATAN BEN-ARYE
- Web page: https://patentgrep.com/patent/US20220031720A1

## CPC

- A61K 31/7012: Compounds having a free or esterified carboxyl group attached, directly or through a carbon chain, to a carbon atom of the saccharide radical, e.g. glucuronic acid, neuraminic acid (gluconic acid A61K31/191; ascorbic acid A61K31/375)
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 39/0011: {Cancer antigens}
- A61K 39/001169: {Tumor associated carbohydrates}
- A61K 39/001171: {Gangliosides, e.g. GM2, GD2 or GD3}
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 35/00: Antineoplastic agents
- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides an active cancer vaccine and specifically an immunogenic compositions of membrane vesicles that serve as biomimetic nanoparticles derived from eukaryotic cell membranes that bear N-glycolylneuraminic acid glycoconjugates. These compositions can elicit beneficial immunological responses for treatment of Neu5Gc-positive tumors. The present invention provides methods of generating and using Neu5Gc-conjugated nanoparticles from eukaryotic cells membranes designated nano-ghosts.

## Claims

### Claim at position 1

1-36. (canceled)

### Claim 37

An immunogenic composition comprising a plurality of membrane vesicles bearing N-glycolylneuraminic acid (Neu5Gc) glycoconjugates; wherein the Neu5Gc glycoconjugates are exposed on the outer surface of the membrane vesicles;
wherein said membrane vesicles are derived from the outer plasma membrane of a eukaryotic cell expressing Neu5Gc; and
wherein the membrane vesicles have an average hydrodynamic diameter in the submicron range.

### Claim 38 (depends on 37)

The immunogenic composition according to claim 37, wherein the membrane vesicles are selected from the group consisting of cell ghosts, exosomes and ectosomes.

### Claim 39 (depends on 38)

The immunogenic composition according to claim 38, wherein the membrane vesicles are cell ghosts.

### Claim 40 (depends on 37)

The immunogenic composition according to claim 37, wherein the average hydrodynamic diameter of the membrane vesicles is within the range of 30-1000 nm.

### Claim 41 (depends on 37)

The immunogenic composition according to claim 37, wherein the eukaryotic cell is a non-human mammalian cell.

### Claim 42 (depends on 41)

The immunogenic composition according to claim 41, wherein the non-human mammalian cell is a non-genetically modified cell that naturally expresses Neu5Gc-glycoconjugates.

### Claim 43 (depends on 42)

The immunogenic composition according to claim 42, wherein said non-human mammalian cell is selected from the group consisting of red blood cells, mesenchymal stem cells, platelets, and cancer cells.

### Claim 44 (depends on 43)

The immunogenic composition according to claim 43, wherein the non-human mammalian cell is a non-human erythrocyte (red blood cell, RBC).

### Claim 45 (depends on 44)

The immunogenic composition according to claim 44, wherein the erythrocyte is porcine-derived.

### Claim 46 (depends on 45)

The immunogenic composition according to claim 45, wherein the porcine derived erythrocyte is from Ggta1−/− knock-out strain.

### Claim 47 (depends on 37)

The immunogenic composition according to claim 37, further comprising at least one additional tumor-associated antigen, wherein the at least one additional tumor-associated antigen is exposed on the outer surface of the membrane vesicle.

### Claim 48 (depends on 37)

The immunogenic composition according to claim 37, further comprising an adjuvant approved for human use.

### Claim 49 (depends on 37)

A vaccine comprising the immunogenic composition according to claim 37.

### Claim 50 (depends on 49)

A method of stimulating an anti-cancer immune response in a subject, the method comprising administering the vaccine of claim 49 to the subject.

### Claim 51 (depends on 50)

The method according to claim 50, wherein the cancer is Neu5Gc-positive.

### Claim 52 (depends on 50)

The method according to claim 50, comprising repeated administrations.

### Claim 53 (depends on 50)

The method according to claim 50, further comprising administering an additional immunotherapeutic drug to the subject.

### Claim 54 (depends on 53)

The method according to claim 53, wherein the vaccine and the additional immunotherapeutic drug are administered substantially simultaneously, concurrently, alternately, successively or according to overlapping schedules.

### Claim 55 (depends on 53)

The method according to claim 53, wherein the additional immunotherapeutic drug is an immune checkpoint inhibitor.

### Claim 56 (depends on 55)

The method according to claim 55, wherein the immune checkpoint inhibitor is selected from PD-1 inhibitor, PD-L1 inhibitor and CTLA-4 inhibitor.

### Claim 57

A method for preparing cell ghosts bearing Neu5Gc-glycoconjugates, the method comprising the steps of:
a) providing a first composition comprising a plurality of isolated eukaryotic cells expressing Neu5Gc glycoconjugates on the outer membrane surface;
b) rupturing the cell membrane of said eukaryotic cells by exposure to a hypotonic buffer followed by centrifugation to remove soluble proteins, thereby obtaining a second composition; and
c) washing the second composition and resuspending in double distilled water to obtain the cell ghosts bearing Neu5Gc-glycoconjugates.

### Claim 58 (depends on 57)

The method according to claim 57, wherein the eukaryotic cells are erythrocytes.

### Claim 59 (depends on 58)

The method according to claim 58, wherein the erythrocytes are porcine-derived erythrocytes.

### Claim 60 (depends on 59)

The method according to claim 59, wherein the porcine-derived erythrocytes are isolated from fresh blood of a porcine α-Gal knockout strain.

### Claim 61 (depends on 57)

The method according to claim 57, wherein the cell ghosts have an average hydrodynamic diameter in the submicron range.

### Claim 62 (depends on 57)

The method according to claim 57, wherein the cell ghosts have an average hydrodynamic diameter within the range of 30-1000 nm, 80-950 nm, 150-900 nm, or 200-800 nm.
